(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Vtv Therapeutics's earnings in 2026 is -$4,756,000.On average, 7 Wall Street analysts forecast VTVT's earnings for 2026 to be -$7,925,042, with the lowest VTVT earnings forecast at -$18,483,462, and the highest VTVT earnings forecast at $83,034. On average, 7 Wall Street analysts forecast VTVT's earnings for 2027 to be -$16,801,817, with the lowest VTVT earnings forecast at -$24,722,115, and the highest VTVT earnings forecast at -$10,337,785.
In 2028, VTVT is forecast to generate -$18,770,128 in earnings, with the lowest earnings forecast at -$32,859,488 and the highest earnings forecast at -$12,579,715.